<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04535531</url>
  </required_header>
  <id_info>
    <org_study_id>NI-MC304</org_study_id>
    <nct_id>NCT04535531</nct_id>
  </id_info>
  <brief_title>A Phase 3 Molluscum Contagiosum Efficacy and Safety Study</brief_title>
  <acronym>B-SIMPLE4</acronym>
  <official_title>A Phase 3 Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study Comparing the Efficacy and Safety of SB206 and Vehicle Gel Once Daily in the Treatment of Molluscum Contagiosum</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novan, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Synteract, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Novan, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 3 multi-center, randomized, double-blind, vehicle-controlled, parallel group&#xD;
      study to be conducted in up to approximately 850 subjects 6 months of age and older with&#xD;
      molluscum contagiosum (MC). Subjects or their caregivers will apply SB206 10.3% or Vehicle&#xD;
      Gel once daily for a minimum of 4 weeks and up to 12 weeks to all lesions identified at&#xD;
      Baseline and new treatable lesions that arise during the course of the study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 3 multi-center, randomized, double-blind, vehicle-controlled, parallel group&#xD;
      study to be conducted in up to approximately 850 subjects 6 months of age and older with&#xD;
      molluscum contagiosum (MC). After obtaining informed consent/assent, subjects who satisfy&#xD;
      entry criteria will be randomized 1:1 (active:vehicle). Subjects receiving current treatment&#xD;
      for MC at the time of the Screening Visit will enter a wash out period of up to 14 days prior&#xD;
      to randomization.&#xD;
&#xD;
      Subjects or their caregivers will apply treatment once daily to all lesions identified at&#xD;
      Baseline and new lesions that arise during treatment for a minimum of 4 weeks and up to 12&#xD;
      weeks. If the investigator determines all lesions are cleared at a visit, the treatment may&#xD;
      stop. If treatment is stopped due to clearance, subjects will continue regularly scheduled&#xD;
      visits through Week 24/ET2. Study drug will be dispensed through Week 12/ET1 in case of&#xD;
      lesion recurrence between study visits. At each visit subsequent to stopping treatment due to&#xD;
      clearance, the investigator will determine if new lesions have occurred since the last visit,&#xD;
      and if so, the subject or caregiver will be instructed by the investigator to re-initiate&#xD;
      treatment. If the subject or caregiver see new lesions or re-occurrence of lesions in between&#xD;
      visits, they should treat these lesions until the next visit. No study drug will be provided&#xD;
      after the Week 12 visit. The subject or caregiver will apply study drug to the individual&#xD;
      lesions. Periocular lesions will be treated if the lesions are at least 2 cm from the edge of&#xD;
      the eye. Subjects will visit the clinic in person at Screening/Baseline, Week 2, Week 4&#xD;
      (unless visit is performed remotely), Week 8, Week 12, and Week 24.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Actual">July 28, 2021</completion_date>
  <primary_completion_date type="Actual">April 28, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete clearance of all treatable MC at Week 12</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Proportion of subjects with complete clearance of all treatable MC at Week 12</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>A lesion count of 0 or 1 of all treatable MC at Week 12</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Proportion of subjects achieving a lesion count of 0 or 1 of all treatable MC at Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90% reduction from Baseline in the number of all treatable MC at Week 12</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Proportion of subjects achieving at least a 90% reduction from Baseline in the number of all treatable MC at Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete clearance of all treatable MC at Week 8</measure>
    <time_frame>8 Weeks</time_frame>
    <description>Proportion of subjects with complete clearance of all treatable MC at Week 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the number of all treatable MC at Week 4</measure>
    <time_frame>4 Weeks</time_frame>
    <description>Percent change from Baseline in the number of all treatable MC at Week 4</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">891</enrollment>
  <condition>Molluscum Contagiosum</condition>
  <arm_group>
    <arm_group_label>SB206 10.3% berdazimer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SB206 10.3% berdazimer topically once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vehicle gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle gel topically once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB206 10.3% berdazimer</intervention_name>
    <description>Topically once daily</description>
    <arm_group_label>SB206 10.3% berdazimer</arm_group_label>
    <other_name>SB206 12% berdazimer sodium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vehicle gel</intervention_name>
    <description>Topically once daily</description>
    <arm_group_label>vehicle gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Be 6 months of age or older, and in good general health;&#xD;
&#xD;
          2. Have a documented informed consent form signed by subject or a parent or legal&#xD;
             guardian and an assent form as required;&#xD;
&#xD;
          3. Have between 3 and 70 treatable MC lesions at Baseline;&#xD;
&#xD;
          4. For women of childbearing potential (WOCBP): Must have a negative urine pregnancy test&#xD;
             prior to randomization and must agree to use an effective method of birth control&#xD;
             during the study; Note: WOCBP and effective methods of birth control are outlined in&#xD;
             Section 9.4.&#xD;
&#xD;
          5. Have a device (phone, tablet, personal computer, etc.) that will support remote&#xD;
             visits, including a camera;&#xD;
&#xD;
          6. Be willing and able to follow study instructions and likely to complete all study&#xD;
             requirements, including remote study visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have strongly suggested sexually transmitted MC and do not agree to refrain from&#xD;
             sexual activities throughout the study period;&#xD;
&#xD;
          2. Are immunosuppressed, have immunodeficiency disorder, or are on immunosuppressive&#xD;
             treatment;&#xD;
&#xD;
          3. Have significant injury on and/or surrounding MC that may impact ability to treat and&#xD;
             count lesions;&#xD;
&#xD;
          4. Have received treatment with topical calcineurin inhibitors or steroids on MC or&#xD;
             within 2 cm of MC lesions within 14 days prior to Baseline;&#xD;
&#xD;
          5. Have received treatment for MC during the 14 days prior to Baseline with&#xD;
             podophyllotoxin, imiquimod, cantharidin, sinecatechins, topical retinoids, oral or&#xD;
             topical zinc, or other homeopathic or over the counter (OTC) products including, but&#xD;
             not limited to, ZymaDerm and tea tree oil, cimetidine and other histamine H2 receptor&#xD;
             antagonists (including Zantac), or any agent that in the opinion of the investigator&#xD;
             may be relevant - (e.g. wart therapies);&#xD;
&#xD;
          6. Have received surgical procedures related to MC (e.g. cryotherapy, curettage) within&#xD;
             14 days prior to Baseline;&#xD;
&#xD;
          7. Have MC only in periocular area;&#xD;
&#xD;
          8. Female subjects who are pregnant, planning a pregnancy or breastfeeding;&#xD;
&#xD;
          9. Have known hypersensitivity to any ingredients of SB206 or Vehicle Gel including&#xD;
             excipients;&#xD;
&#xD;
         10. Have participated in a previous study with a berdazimer containing product (i.e.&#xD;
             SB204, SB206, SB208, SB414);&#xD;
&#xD;
         11. Have more than one other family member participating in this study (NI-MC304);&#xD;
&#xD;
         12. Have at least 1 family member currently participating in a study, other than this&#xD;
             study, with a berdazimer containing product (i.e. SB204, SB206, SB208, SB414);&#xD;
&#xD;
         13. Have participated in any other trial of an interventional investigational drug or&#xD;
             device within 14 days or concurrent participation in another interventional research&#xD;
             study;&#xD;
&#xD;
         14. History or presence of clinically significant medical, psychiatric, or emotional&#xD;
             condition that, in opinion of the investigator, would compromise the safety of the&#xD;
             subject or the quality of the data.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tomoko Maeda Chubachi, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Novan, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site #312</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #101</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #272</name>
      <address>
        <city>Rogers</city>
        <state>Arkansas</state>
        <zip>72758</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #336</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #329</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site# 348</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #161</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #327</name>
      <address>
        <city>Thousand Oaks</city>
        <state>California</state>
        <zip>91320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #325</name>
      <address>
        <city>Greenwood Village</city>
        <state>Colorado</state>
        <zip>80111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #335</name>
      <address>
        <city>Apopka</city>
        <state>Florida</state>
        <zip>32703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #342</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33428</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #333</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #334</name>
      <address>
        <city>Homestead</city>
        <state>Florida</state>
        <zip>33030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #314</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #278</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33165</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #341</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32829</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #227</name>
      <address>
        <city>Sanford</city>
        <state>Florida</state>
        <zip>32771</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #305</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33163</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #116</name>
      <address>
        <city>Newnan</city>
        <state>Georgia</state>
        <zip>30263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #340</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #253</name>
      <address>
        <city>Rolling Meadows</city>
        <state>Illinois</state>
        <zip>60008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #288</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #310</name>
      <address>
        <city>Plainfield</city>
        <state>Indiana</state>
        <zip>46168</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #328</name>
      <address>
        <city>Bowling Green</city>
        <state>Kentucky</state>
        <zip>42101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #347</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40517</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site # 117</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #294</name>
      <address>
        <city>Owensboro</city>
        <state>Kentucky</state>
        <zip>42301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #321</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site# 349</name>
      <address>
        <city>Covington</city>
        <state>Louisiana</state>
        <zip>70433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #332</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #297</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #330</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20854</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #346</name>
      <address>
        <city>Brighton</city>
        <state>Massachusetts</state>
        <zip>02135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #274</name>
      <address>
        <city>Clarkston</city>
        <state>Michigan</state>
        <zip>48346</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #121</name>
      <address>
        <city>New Brighton</city>
        <state>Minnesota</state>
        <zip>55112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #338</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #201</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #331</name>
      <address>
        <city>Verona</city>
        <state>New Jersey</state>
        <zip>07044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #279</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #250</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #265</name>
      <address>
        <city>Sugarloaf</city>
        <state>Pennsylvania</state>
        <zip>18249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #311</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02866</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #295</name>
      <address>
        <city>Fountain Inn</city>
        <state>South Carolina</state>
        <zip>29644</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #255</name>
      <address>
        <city>Summerville</city>
        <state>South Carolina</state>
        <zip>29486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #291</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #326</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #316</name>
      <address>
        <city>Murfreesboro</city>
        <state>Tennessee</state>
        <zip>37130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #337</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77087</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #299</name>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <zip>75605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #224</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #281</name>
      <address>
        <city>Layton</city>
        <state>Utah</state>
        <zip>84041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #345</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #267</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #339</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #343</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 27, 2020</study_first_submitted>
  <study_first_submitted_qc>August 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 2, 2020</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Molluscum Contagiosum</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

